BioCon Limited Hits Roche First, Set To Launch Biosimilar Of Breast Cancer Drug Herceptin
Published: Jan 21, 2014
Biocon Ltd said its generic version of Roche's Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc. About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.
Help employers find you! Check out all the jobs and post your resume.